Patients with IRAK4 high expression had a survival advantage compared with low group in BLCA (n = 406, p = 0.013, Figure 3(t)), PAAD (n = 177, p = 0.020, Figure 3(w)), THYM (n = 118, p = 0.011, Figure 3(x)), and UCEC (n = 544, p = 0.001, Figure 3(y)). The gene discussed is IRAK4; the disease is bladder transitional cell carcinoma.